



**Veterans
Administration**

Medical Center

150 Muir Road
Martinez CA 94553

RECEIVED
JAN 22 AM 9:30
REGION VISE

612/11R

In Reply Refer To:

JAN 21 1987

U.S. Nuclear Regulatory Commission
1450 Maria Lane, Suite 210
Walnut Creek, CA 94596

THRU: Chief, Nuclear Medicine Service (115)
Department of Medicine and Surgery
Veterans Administration Central Office
810 Vermont Avenue, N.W.
Washington, D.C. 20420

SUBJ: Request for amendment to Materials License Number 04-02956-02

1. We request an amendment to our Nuclear Regulatory Commission byproduct material license number 04-02956-02. Specifically we wish to have Kenneth Mido, M.D., Michael A. Dubick, Ph.D., and Robert C. Marshall, M.D. designated as Authorized Users for the following materials and uses:

Kenneth Mido, M.D.

Groups I, II, III, Xenon-133,
Iodine-131 for the treatment of
hyperthyroidism and/or cardiac
conditions and for the treatment
of thyroid carcinoma, Americium-241
Anatomical marker, in vitro
studies, animal studies

Michael A. Dubick, Ph.D.

in vitro studies, animal studies

Robert C. Marshall, M.D.

in vitro studies, animal studies

Dr. Mido was certified by the American Board of Radiology in Diagnostic Radiology with Special Competence in Nuclear Radiology in June 1985. Dr. Mido has been notified that he successfully passed the certifying examination administered on September 6, 1986 by the American Board of Nuclear Medicine and is therefore certified by the board. Form NRC-113 Supplement B describing Dr. Mido's clinical experience with the therapeutic use of Iodine-131 is attached. Forms NRC-113 Supplement A describing Dr. Dubick's and Dr. Marshall's training and experience are also attached.

8702090223 870126
REG 5 LIC 30
04-02956-02 PDR


FEE EXEMPT

70516

2.

U.S. Nuclear Regulatory Commission

2. we wish to have Adhip Rajumdar, Ph.D., and Marguerite T. Hays, M.D., removed from our license as Authorized Users since they are no longer affiliated with our medical center.



C.H. Hix
Director

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER Robert C. Marshall, M.D.	2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE California
--	--

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
Internal Medicine		April 1974

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION	July '75 - June '77 - Yale University School of Medicine July '77 - Aug. '86 - UCLA Center for Health Science	20	200
b. RADIATION PROTECTION	Same as above	10	20
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	Same as above	10	100
d. RADIATION BIOLOGY	Same as above	10	0
e. RADIOPHARMACEUTICAL CHEMISTRY		0	0

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
		See accompanying Sheet		

5.

<u>Isotope</u>	<u>Max. Amt.</u>	<u>Where Gained</u>	<u>Duration of Experience</u>	<u>Type of Use</u>
Tc-99m as pertechnetate or sulfur colloid	20mCi 10mCi	Yale University School of Medicine	July '75- June '77	Development of first-pass technique of assessing ventricular function in man
Tc-99m labeled red blood cells	15mCi	UCLA Center for Health Sciences	July '77- June '79	Use of multiple gated equilibrium technique to assess ventricular function in man
N-13 ammonia and F-18 fluoro deoxyglucose	20mCi 8mCi	UCLA Center for Health Sciences	April '79- Dec. '83	Assessment of myocardial perfusion and glucose utilization in man with positron tomography
H-3 glucose, C-14 glucose, and C-14 palmitate	<100uCi	UCLA Center for Health Sciences	April '78- Dec. '84	Assessment of myocardial glucose metabolism and free-fatty acid and metabolism in isolated hearts
H-3 glucose, F-18 fluoro deoxyglucose, Tc-99m labeled RBC and C-14 sorbital	<100uCi	UCLA Center for Health Sciences	April '78- April '84	Tracer kinetic modeling.

**TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER**

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER Robert C. Marshall, M.D.	2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE California
--	--

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
Internal Medicine		April 1974

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION	July '75 - June '77 - Yale University School of Medicine July '77 - Aug. '86 - UCLA Center for Health Science	20	200
b. RADIATION PROTECTION	Same as above	10	20
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	Same as above	10	100
d. RADIATION BIOLOGY	Same as above	10	0
e. RADIOPHARMACEUTICAL CHEMISTRY		0	0

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
		See accompanying Sheet		

**TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER**

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

Michael A. Dubick, Ph.D.

2. STATE OR TERRITORY IN
WHICH LICENSED TO
PRACTICE MEDICINE**3. CERTIFICATION**SPECIALTY BOARD
ACATEGORY
BMONTH AND YEAR CERTIFIED
C**4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES**FIELD OF TRAINING
ALOCATION AND DATE(S) OF TRAINING
B

TYPE AND LENGTH OF TRAINING

LECTURE/
LABORATORY
COURSES
(Hours)
CSUPERVISED
LABORATORY
EXPERIENCE
(Hours)
Da. RADIATION PHYSICS AND
INSTRUMENTATIONUniversity of Southern
California Fall '76

1

1

b. RADIATION PROTECTION

University of Southern
California, Fall '76
University of California, Davis '79

2

1

c. MATHEMATICS PERTAINING TO
THE USE AND MEASUREMENT
OF RADIOACTIVITYUniversity of Southern Cal.
Fall '75

10

25

d. RADIATION BIOLOGY

University of Southern Cal.
Fall '75

10

25

e. RADIOPHARMACEUTICAL
CHEMISTRYUniversity of Southern Cal.
Fall '75

1

--

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE

MAXIMUM AMOUNT

WHERE EXPERIENCE WAS GAINED

DURATION OF EXPERIENCE

TYPE OF USE

5. Experience with radiation

<u>Isotope</u>	<u>Max. Amt.</u>	<u>Where Gained</u>	<u>Duration of Experience</u>
H-3	5mCi	University of Southern California	July 76 - June 78
H-3	15mCi up to 50mCi when used sodium cyanoborohydride	University of California, Davis	Sept. 78 - Dec. 83
H-3	10mCi	V.A. Medical Center, Martinez	Dec. 83 - to date
C-14	1mCi	University of California, Davis	Jan. 80 - Feb. 83
P-32	250uCi	University of Southern California	July 75 - June 76
I-125	5mCi	University of California, Davis	Sept. 78 - Dec. 83
	10mCi	V.A. Medical Center, Martinez	Dec. 83 - to date
Cr-51	1mCi	V.A. Medical Center, Martinez	April 86 - July 86

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

FULL NAME

Kenneth Mido, M.D.

STREET ADDRESS

1571 Ninth Ave. #1

CITY

San Francisco

STATE

CA

ZIP CODE

94122

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	100	
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME	25	
	LIVER FUNCTION STUDIES	-	
	FAT ABSORPTION STUDIES	-	
	KIDNEY FUNCTION STUDIES	239	
	IN VITRO STUDIES	MULTIPLE	
OTHER	SHILLINGS	48	
I-125	DETECTION OF THROMBOSIS	-	
I-131	THYROID IMAGING	89	
P-32	EYE TUMOR LOCALIZATION	-	
Se-75	PANCREAS IMAGING	-	
I-131	CISTERNOGRAPHY	24	
OTHER	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	402	
	67 Gallium	60	
Tc-99m	BRAIN IMAGING	1	
	CARDIAC IMAGING	687	
	THYROID IMAGING	306	
	SALIVARY GLAND IMAGING	-	
	BLOOD POOL IMAGING	300	
	PLACENTA LOCALIZATION	-	
	LIVER AND SPLEEN IMAGING	220	
	LUNG IMAGING	491	
OTHER	BONE IMAGING	2184	
	Hepatobiliary	114	

Thallium

880

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	-	
P-32 (Colloidal)	INTRACAVITARY TREATMENT	-	
I-131	TREATMENT OF THYROID CARCINOMA	3	
	TREATMENT OF HYPERTHYROIDISM	10	
Au-198	INTRACAVITARY TREATMENT	-	
Co-60 or Cs-137	INTERSTITIAL TREATMENT	-	
	INTRACAVITARY TREATMENT	-	
I-125 or Ir-192	INTERSTITIAL TREATMENT	-	
Co-60 or Cs-137	TELETHERAPY TREATMENT	-	
Sr-90	TREATMENT OF EYE DISEASE	-	
	RADIOPHARMACEUTICAL PREPARATION	MULTIPLE	
Mo-99/ Tc-99m	GENERATOR	11	
Sr-113/ In-113m	GENERATOR	11	
Tc-99m	REAGENT KITS	11	
Other	In WBC	370	

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR
I. R. McDougall, MB, ChB, PhD

b. NAME OF INSTITUTION
Stanford Medical Center

c. MAILING ADDRESS
300 Pasteur Drive

d. CITY
Stanford, CA 94305

e. MATERIALS LICENSE NUMBER(S)
0676-43

6. PRECEPTOR'S SIGNATURE

I. Ross in Langell

7. PRECEPTOR'S NAME (Please type or print)

I. Ross McDougall, MB, ChB, PhD

8. DATE

11/12/86